Document Classification

Section Type: RESULTS

Text: Bivalirudin alone, as compared with heparin plus a glycoprotein IIb/IIIa inhibitor, was associated with a noninferior rate of the composite ischemia end point (7. 8 % and 7. 3 %, respectively ; P = 0. 32 ; relative risk, 1. 08 ; 95 % confidence interval [CI], 0. 93 to 1. 24) and significantly reduced rates of major bleeding (3. 0 % vs. 5. 7 % ; P < 0. 001 ; relative risk, 0. 53 ; 95 % CI, 0. 43 to 0. 65) and the net clinical outcome end point (10. 1 % vs. 11. 7 % ; P = 0. 02 ; relative risk, 0. 86 ; 95 % CI, 0. 77 to 0. 97).